Literature DB >> 24990093

Different apoptotic effects of [Pt(O,O'-acac)(γ-acac)(DMS)] and cisplatin on normal and cancerous human epithelial breast cells in primary culture.

Carla Vetrugno1, Antonella Muscella, Francesco Paolo Fanizzi, Luca Giulio Cossa, Danilo Migoni, Sandra Angelica De Pascali, Santo Marsigliante.   

Abstract

BACKGROUND AND
PURPOSE: The aim of this study was to determine whether [platinum (Pt)(O,O'-acetylacetonate (acac))(γ-acac)(dimethylsulphide (DMS))] is differentially cytotoxic in normal and cancer cells, and to measure comparative levels of cytotoxicity compared with cisplatin in the same cells. EXPERIMENTAL APPROACH: We performed experiments on cancerous and normal epithelial breast cells in primary culture obtained from the same patients. The apoptotic effects [Pt(O,O'-acac)(γ-acac)(DMS)] and cisplatin in cancerous and normal breast cells were compared. KEY
RESULTS: Cancer cells were more sensitive to [Pt(O,O'-acac)(γ-acac)(DMS)] (IC50 = 5.22 ± 1.2 μmol·L(-1)) than normal cells (IC50 = 116.9 ± 8.8 μmol·L(-1)). However, the difference was less strong when cisplatin was used (IC50 = 96.0 ± 6.9 and 61.9 ± 6.1 μmol·L(-1) for cancer and normal cells respectively). Both compounds caused reactive oxygen species (ROS) production with different mechanisms: [Pt(O,O'-acac)(γ-acac)(DMS)] quickly activated NAD(P)H oxidase while cisplatin caused a slower formation of mitochondrial ROS. Cisplatin and [Pt(O,O'-acac)(γ-acac)(DMS)] caused activation of caspases, proteolysis of PARP and modulation of Bcl-2, Bax and Bid. [Pt(O,O'-acac)(γ-acac)(DMS)] also caused leakage of cytochrome c from the mitochondria. Overall, these processes proceeded more quickly in cells treated with [Pt(O,O'-acac)(γ-acac)(DMS)] compared with cisplatin. [Pt(O,O'-acac)(γ-acac)(DMS)] effects were faster and quantitatively greater in cancer than in normal cells. [Pt(O,O'-acac)(γ-acac)(DMS)] caused a fast decrease of mitochondrial membrane potential, especially in cancer cells. CONCLUSIONS AND IMPLICATIONS: [Pt(O,O'-acac)(γ-acac)(DMS)] was specific to breast cancer cells in primary culture, and this observation makes this compound potentially more interesting than cisplatin.
© 2014 The British Pharmacological Society.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24990093      PMCID: PMC4253461          DOI: 10.1111/bph.12831

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  52 in total

Review 1.  Proapoptotic multidomain Bcl-2/Bax-family proteins: mechanisms, physiological roles, and therapeutic opportunities.

Authors:  J C Reed
Journal:  Cell Death Differ       Date:  2006-06-02       Impact factor: 15.828

2.  Hard/soft selectivity in ligand substitution reactions of beta-diketonate platinum(II) complexes.

Authors:  Sandra A De Pascali; Paride Papadia; Serena Capoccia; Luciano Marchiò; Maurizio Lanfranchi; Antonella Ciccarese; Francesco P Fanizzi
Journal:  Dalton Trans       Date:  2009-07-31       Impact factor: 4.390

Review 3.  A better platinum-based anticancer drug yet to come?

Authors:  Ulrike Olszewski; Gerhard Hamilton
Journal:  Anticancer Agents Med Chem       Date:  2010-05       Impact factor: 2.505

4.  BCL-2 antisense and cisplatin combination treatment of MCF-7 breast cancer cells with or without functional p53.

Authors:  Hesham Basma; Hesham El-Refaey; Magdalene K Sgagias; Kenneth H Cowan; Xu Luo; Pi-Wan Cheng
Journal:  J Biomed Sci       Date:  2005-10-14       Impact factor: 8.410

Review 5.  Metal complexes in medicine with a focus on enzyme inhibition.

Authors:  Chi-Ming Che; Fung-Ming Siu
Journal:  Curr Opin Chem Biol       Date:  2009-12-16       Impact factor: 8.822

Review 6.  Metal complexes, their cellular targets and potential for cancer therapy.

Authors:  Di Chen; Vesna Milacic; Michael Frezza; Q Ping Dou
Journal:  Curr Pharm Des       Date:  2009       Impact factor: 3.116

Review 7.  Status of non-classical mononuclear platinum anticancer drug development.

Authors:  Jinchao Zhang; Dandan Liu; Yaping Li; Jing Sun; Liwei Wang; Aimin Zang
Journal:  Mini Rev Med Chem       Date:  2009-10       Impact factor: 3.862

8.  [Pt(O,O'-acac)(gamma-acac)(DMS)], a new Pt compound exerting fast cytotoxicity in MCF-7 breast cancer cells via the mitochondrial apoptotic pathway.

Authors:  A Muscella; N Calabriso; F P Fanizzi; S A De Pascali; L Urso; A Ciccarese; D Migoni; S Marsigliante
Journal:  Br J Pharmacol       Date:  2007-11-19       Impact factor: 8.739

Review 9.  Mitochondria: a hub of redox activities and cellular distress control.

Authors:  Poonam Kakkar; B K Singh
Journal:  Mol Cell Biochem       Date:  2007-06-12       Impact factor: 3.396

10.  Iron(III)-salen damages DNA and induces apoptosis in human cell via mitochondrial pathway.

Authors:  Getachew A Woldemariam; Subhrangsu S Mandal
Journal:  J Inorg Biochem       Date:  2007-11-29       Impact factor: 4.155

View more
  7 in total

1.  Antitumour and antiangiogenic activities of [Pt(O,O'-acac)(γ-acac)(DMS)] in a xenograft model of human renal cell carcinoma.

Authors:  A Muscella; C Vetrugno; F Biagioni; N Calabriso; M T Calierno; F Fornai; S A De Pascali; S Marsigliante; F P Fanizzi
Journal:  Br J Pharmacol       Date:  2016-07-22       Impact factor: 8.739

2.  [Pt(O,O'-acac)(γ-acac)(DMS)]: Alternative Strategies to Overcome Cisplatin-Induced Side Effects and Resistance in T98G Glioma Cells.

Authors:  Valentina Astesana; Pawan Faris; Beatrice Ferrari; Stella Siciliani; Dmitry Lim; Marco Biggiogera; Sandra Angelica De Pascali; Francesco Paolo Fanizzi; Elisa Roda; Francesco Moccia; Maria Grazia Bottone
Journal:  Cell Mol Neurobiol       Date:  2020-05-19       Impact factor: 5.046

3.  Synthesis and Evaluation of the Cytotoxic Activity of Water-Soluble Cationic Organometallic Complexes of the Type [Pt(η1-C2H4OMe)(L)(Phen)]+ (L = NH3, DMSO; Phen = 1,10-Phenanthroline).

Authors:  Federica De Castro; Erika Stefàno; Danilo Migoni; Giorgia N Iaconisi; Antonella Muscella; Santo Marsigliante; Michele Benedetti; Francesco P Fanizzi
Journal:  Pharmaceutics       Date:  2021-04-30       Impact factor: 6.321

4.  [Pt(O,O'-acac)(γ-acac)(DMS)] alters SH-SY5Y cell migration and invasion by the inhibition of Na+/H+ exchanger isoform 1 occurring through a PKC-ε/ERK/mTOR Pathway.

Authors:  Antonella Muscella; Carla Vetrugno; Nadia Calabriso; Luca Giulio Cossa; Sandra Angelica De Pascali; Francesco Paolo Fanizzi; Santo Marsigliante
Journal:  PLoS One       Date:  2014-11-05       Impact factor: 3.240

5.  Apoptosis by [Pt(O,O'-acac)(γ-acac)(DMS)] requires PKC-δ mediated p53 activation in malignant pleural mesothelioma.

Authors:  Antonella Muscella; Carla Vetrugno; Luca Giulio Cossa; Giovanna Antonaci; Amilcare Barca; Sandra Angelica De Pascali; Francesco Paolo Fanizzi; Santo Marsigliante
Journal:  PLoS One       Date:  2017-07-12       Impact factor: 3.240

6.  In Vitro and In Vivo Antitumor Activity of [Pt(O,O'-acac)(γ-acac)(DMS)] in Malignant Pleural Mesothelioma.

Authors:  Antonella Muscella; Carla Vetrugno; Luca Giulio Cossa; Giovanna Antonaci; Francesco De Nuccio; Sandra Angelica De Pascali; Francesco Paolo Fanizzi; Santo Marsigliante
Journal:  PLoS One       Date:  2016-11-02       Impact factor: 3.240

7.  Response of Cisplatin Resistant Skov-3 Cells to [Pt(O,O'-Acac)(γ-Acac)(DMS)] Treatment Revealed by a Metabolomic ¹H-NMR Study.

Authors:  Federica De Castro; Michele Benedetti; Giovanna Antonaci; Laura Del Coco; Sandra Angelica De Pascali; Antonella Muscella; Santo Marsigliante; Francesco Paolo Fanizzi
Journal:  Molecules       Date:  2018-09-09       Impact factor: 4.411

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.